Stephen Garbacz
Corporate Officer/Principal at Tessera Therapeutics, Inc.
Stephen Garbacz active positions
| Companies | Position | Start | End |
|---|---|---|---|
Tessera Therapeutics, Inc.
 Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2021-04-30 | - |
Career history of Stephen Garbacz
Former positions of Stephen Garbacz
| Companies | Position | Start | End |
|---|---|---|---|
| ANIKA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 2019-05-05 | 2021-04-30 |
| SPERO THERAPEUTICS, INC. | Chief Operating Officer | 2014-12-31 | - |
| Corporate Officer/Principal | 2014-12-31 | - | |
| EPIZYME, INC. | Comptroller/Controller/Auditor | 2014-09-30 | 2015-02-08 |
| Director of Finance/CFO | 2012-07-31 | - |
Training of Stephen Garbacz
| The Leonard N Stern School of Business | Masters Business Admin |
| George Mason University | Undergraduate Degree |
Statistics
International
| United States | 7 |
Operational
| Comptroller/Controller/Auditor | 2 |
| Corporate Officer/Principal | 2 |
| Director of Finance/CFO | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| SPERO THERAPEUTICS, INC. | Health Technology |
| ANIKA THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Stephen Garbacz
- Experience
